Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema

Business Wire November 5, 2021

Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10

Business Wire October 27, 2021

Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

Business Wire October 21, 2021

Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit

Business Wire October 18, 2021

Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit

Business Wire October 12, 2021

Astria Therapeutics to Present at Upcoming Investor Conferences

Business Wire September 10, 2021

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

Business Wire September 8, 2021

Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Business Wire August 9, 2021

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Business Wire August 4, 2021

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Business Wire July 7, 2021

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Business Wire May 14, 2021

 Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Business Wire May 13, 2021

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Business Wire March 11, 2021

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   

Business Wire March 2, 2021

Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

Business Wire January 29, 2021

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Business Wire November 12, 2020

Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy

Business Wire October 26, 2020

Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society

Business Wire September 28, 2020

Catabasis Pharmaceuticals to Present During the Virtual 25th International Congress of the World Muscle Society

Business Wire September 23, 2020

Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer

Business Wire September 21, 2020